Opinions
James Hodgins
VSM MedTech Ltd.
VSM-T
DON'T BUY
Apr 21, 2014
$0.050
Stock price when the opinion was issued
biotechnology
pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
DON'T BUY
Has very good technology, but unfortunately it is still in the early stages of being rolled out to the medical community. In the bottom 15% of his database. Earnings estimates have been shaved by about 5% in the last 90 days and 20% in the last 60 days. Most recent quarter had a negative earnings surprise. Expected to lose $0.23 in ’06 and $0.15 in ’07.
biotechnology
pharmaceutical
Likes this. Core business is selling broadcast equipment to cable and telcos. Have done a great job of creating shareholder value by selling off non-core assets such as wireless spectrum and real estate in Saskatchewan. Thinks they are kind of getting to the end of the line and he has sold his position.